Research Project

Project Title:	A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLINDED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN PATIENTS WITH C3 GLOMERULOPATHY OR IMMUNE-COMPLEX MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
Project Type:	Clinical Trial, Enrolment terminated Adjunct biobank: Serum, Plasma, Urine
Disease group(s):	Immune glomerulopathies
Project Summary:	This is a placebo-controlled, double-blinded, phase 3 study in patients with clinical and pathologic evidence of primary C3G or IC-MPGN. Participants will be randomly assigned 1:1 to either the pegcetacoplan group (pegcetacoplan treatment throughout the RCP and open-label period) or the placebo group (placebo treatment during the RCP and pegcetacoplan treatment during the open-label period).
Lead principal investigator(s):	Giovanni Montini, Milan
Co-investigator(s):	Antonio Mastrangelo, Milan
Project Period:	07/2022 - 07/2050
Sponsors:	Industry
Project web page:	https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-003767-25/ES
EudraCT Nr.:	2020-003767-25